- successfully raised approximately $500K through a private placement of convertible notes in November 2012, which was the second tranche of a financing that raised an aggregate of $1.32 million;
- entered into a marketing agreement for Neutrolin ® with MKM Co-Pharma GmbH in January 2013; and
- raised $533,000 in gross proceeds from the sale to an existing institutional investor of shares of our Series A non-voting convertible preferred stock and related common stock warrants in February 2013.
CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial results for the year ended December 31, 2012. Fourth Quarter 2012 and First Quarter 2013 Financing Developments During the fourth quarter of 2012 and first quarter of 2013, CorMedix: